Paroxetine Use Throughout Pregnancy: Does It Pose Any Risk to the Neonate?
- 1 January 2004
- journal article
- Published by Taylor & Francis in Journal of Toxicology: Clinical Toxicology
- Vol. 42 (1) , 97-100
- https://doi.org/10.1081/clt-120028753
Abstract
A newborn of a SSRI‐treated mother presented with lethargy, no crying, and no response to tactile stimulation. EEG findings were abnormal. Laboratory and clinical evaluations were normal. He recovered at the age of two weeks. Serotonin is a neurotransmitter that has an important roll in pain modulation during fetal neurodevelopment. We suspect these symptoms are attributed to the intrauterine exposure to paroxetine, through modulation of pain signals.Keywords
This publication has 12 references indexed in Scilit:
- Perinatal Outcome Following Third Trimester Exposure to ParoxetineArchives of Pediatrics & Adolescent Medicine, 2002
- Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain ResponsePediatric Research, 2002
- Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitorsActa Paediatrica, 2001
- Neonatal paroxetine withdrawal syndromeArchives of Disease in Childhood: Fetal & Neonatal, 2001
- Pregnancy Outcome Following Maternal Use of the New Selective Serotonin Reuptake InhibitorsJAMA, 1998
- Neonatal Pharmacology of PainPublished by Springer Nature ,1997
- A comparison of the post‐marketing safety of four selective serotonin re‐uptake inhibitors including the investigation of symptoms occurring on withdrawalBritish Journal of Clinical Pharmacology, 1996
- Birth Outcomes in Pregnant Women Taking FluoxetineNew England Journal of Medicine, 1996
- Effects of Third Trimester Fluoxetine Exposure on the NewbornJournal of Clinical Psychopharmacology, 1995
- Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT2 receptors in cerebral cortex: Lack of correlation between 5-HT2 receptors and serotonin-mediated behaviourNeuropharmacology, 1985